News Headlines Article

Medivation snags $90M from Astellas as FDA expands use of prostate cancer drug
San Francisco Business Times

An expanded label on Medivation Inc.’s signature prostate cancer drug will net the San Francisco company an additional $90 million from partner Astellas Pharma Inc. The Food and Drug Administration said Xtandi, which the agency approved in August 2012 to treat men with metastatic castration-resistant prostate cancer who previously received the chemotherapy drug docetaxel, now can be used before chemotherapy, the companies said Wednesday.